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utations in P0 (MPZ), the major myelin protein of
the peripheral nervous system, cause the inherited
demyelinating neuropathy Charcot-Marie-Tooth
disease type 1B. P0 is a member of the immunoglobulin
superfamily and functions as a homophilic adhesion
molecule. We now show that point mutations in the cyto-
plasmic domain that modify a PKC target motif (RSTK) or
an adjacent serine residue abolish P0 adhesion function
and can cause peripheral neuropathy in humans. Consistent
 
with these data, PKC
 
  
 
along with the PKC binding protein
 
RACK1 are immunoprecipitated with wild-type P0, and
M
 
inhibition of PKC activity abolishes P0-mediated adhesion.
Point mutations in the RSTK target site that abolish adhesion
do not alter the association of PKC with P0; however, deletion
of a 14 amino acid region, which includes the RSTK motif,
does abolish the association. Thus, the interaction of PKC
 
 
 
with the cytoplasmic domain of P0 is independent of speciﬁc
target residues but is dependent on a nearby sequence. We
conclude that PKC-mediated phosphorylation of speciﬁc
residues within the cytoplasmic domain of P0 is necessary
for P0-mediated adhesion, and alteration of this process
can cause demyelinating neuropathy in humans.
 
Introduction
 
Myelin is a multilamellar structure that surrounds axons
 
in both the central nervous system and the peripheral
nervous system (PNS),* facilitating nerve conduction. P0,
a transmembrane protein of the Ig superfamily, is the
major myelin structural protein in the PNS, expressed
exclusively by myelinating Schwann cells and necessary for
normal myelin structure and function. In mice, the absence
of P0 (Giese et al., 1992; Martini et al., 1995) or overex-
pression of P0 (Wrabetz et al., 2000) results in hypomyelin-
ation and peripheral neuropathy. In addition, mutations
in the human P0 gene cause the demyelinating peripheral
neuropathy Charcot-Marie-Tooth disease 1B, the more
severe Dejerine-Sottas syndrome, and congenital hypo-
myelination, all associated with muscle weakness, atro-
phy, and sensory loss (for review see Nelis et al., 1999;
Shy et al., 2001).
P0 functions as a homophilic adhesion molecule in vitro
(Filbin et al., 1990; Filbin and Tennekoon, 1993), and this
activity may mediate compaction of adjacent leaflets in pe-
ripheral nerve myelin. Analysis of the crystal structure of
the P0 extracellular domain indicates that P0 molecules
have the potential to interact in cis to form homotetra-
mers, and these interact in trans to mediate homophilic ad-
hesion (Shapiro et al., 1996). Consistent with this model,
mutation of several of the amino acid residues critical for
these putative cis and trans interactions can cause the
inherited demyelinating peripheral neuropathy, CMT1B
(Warner et al., 1996; Nelis et al., 1999).
The cytoplasmic domain of P0 is also important for its
function, and mutations in this region result in loss of P0-
mediated homophilic adhesion in vitro (Wong and Filbin,
1994). Coexpression of both wild-type and cytoplasmically
truncated P0 causes loss of wild-type function, presumably
due to a dominant negative effect of the truncated molecule
(Wong and Filbin, 1996). Mutations within the P0 cyto-
plasmic domain are also found in patients with inherited de-
myelinating neuropathies, some of which have very severe
clinical phenotypes (Nelis et al., 1999; Shy et al., 2001).
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These data demonstrate a critical role for the cytoplasmic do-
main of P0 in mediating homophilic adhesion and in the mo-
lecular pathogenesis of inherited demyelinating neuropathies.
We now demonstrate that deletion of a 14 amino acid se-
quence in the cytoplasmic domain of P0 abolishes adhesive
function. Point mutations in this region that alter a PKC
substrate motif (RSTK) and mutation of an adjacent serine
residue (S204) are critical to P0 adhesive function. More-
over, PKC
 
 
 
 and the receptor for activated C kinase
(RACK1) are coimmunoprecipitated from cells expressing
wild-type P0 but not P0 bearing a deletion of 14 amino acid
sequence. In addition, inhibition of PKC activity results in
loss of P0-mediated adhesion. We have also identified a mu-
tation of the initial arginine of the PKC substrate motif to a
serine residue (R198S) in a patient with CMT1B, and we
find that cells expressing P0 bearing this mutation fail to
form homophilic adhesions. These data indicate that PKC-
mediated phosphorylation is an important component of
the regulation of P0-mediated adhesion and demonstrate
that alteration of this process can cause demyelinating neu-
 
ropathy in humans. This is the first glimpse of the molecular
machinery that regulates the function of P0 in myelination.
 
Results
 
A subterminal 13 amino acid sequence in the 
cytoplasmic domain of P0 is essential for adhesion
 
To define the regions of the cytoplasmic domain of P0 that
are essential for homophilic adhesion, we stably transfected
mouse L cells and HeLa cells with cDNAs encoding wild-
type P0 or P0 deletion mutants lacking the COOH-termi-
nal 13 (
 
 
 
13), 28 (
 
 
 
28), 43 (
 
 
 
43), or 59 amino acids (
 
 
 
59).
Expression of the transfected P0 constructs was determined
by reverse transcription (RT)-PCR using specific primers for
each construct and by Western blotting. RT-PCR reveals
that all constructs were expressed in relatively equal amounts
in both cell types (Fig. 1 B shows L cells). To ensure that
protein was expressed and inserted in the plasma membrane,
we labeled live cells with a membrane impermeable biotin-
ylation reagent followed by immunoprecipitation with anti-
P0 antibody. The immunoprecipitated material was fraction-
ated by SDS-PAGE, transferred to polyvinylene difluoride
(PVDF) membranes, and probed with HRP-streptavidin.
Each of the P0 constructs is expressed at the cell surface (Fig.
1 C shows L cells).
Cells expressing each of the deletion mutants were assayed
for their ability to form homophilic adhesions as measured
by binding of single cells expressing P0 constructs to a con-
fluent layer of cells expressing wild-type P0. Both L cells and
HeLa cells expressing 
 
 
 
13 were comparable to the same cell
types expressing wild-type P0 (Fig. 2, A and B). However,
P0-mediated adhesion was reduced dramatically in all cell
lines with deletions of 28 amino acids or greater (Fig. 2, A
and B). This suggests that the sequence between amino acids
193 and 206 is essential for P0-mediated cell–cell adhesion.
This region contains three serine residues that are phosphor-
ylated in mouse sciatic nerve: S197, S199, and S204 (Hilmi
et al., 1995). These residues are conserved in the human P0
sequence. Furthermore, serine 199 is part of a PKC recogni-
tion motif (198-RSTK-201) (Kishimoto et al., 1985;
Woodgett et al., 1986), suggesting that phosphorylation me-
diated by PKC is critical to P0 adhesive function.
Since it has been reported that expression of P0 in HeLa
cells results in upregulation of cadherin expression (Doyle et
al., 1995), we were careful to perform all P0 adhesion assays in
the absence of Ca
 
2
 
 
 
, which is necessary for cadherin-mediated
adhesion. Additionally, we examined both HeLa and L cells
bearing each of the P0 deletion constructs for cadherin expres-
sion using a pan cadherin antibody to blot equivalent amounts
of cell lysate. In agreement with the previous observations,
cadherin and the cadherin-associated protein 
 
 
 
-catenin are up-
regulated in HeLa cells stably transfected with pCMV Tag4
containing the full-length wild-type P0 but not in L cells simi-
larly transfected (unpublished data). Furthermore, among
HeLa cells upregulation requires the same region of the mole-
cule that is essential for adhesion function, amino acids 193–
206 (unpublished data). The two cell lines do differ in their
basal level of cadherin expression: HeLa cells express a small
amount of cadherin, whereas L cells do not express detectable
levels of cadherin. Thus, upregulation of cadherin expression
Figure 1. Expression of full-length P0 and P0 deletion mutants in 
transfected L cells. (A) Diagram of P0 cDNA showing the relative 
positions of the primers used to clone full-length and mutant P0. 
The same 5  primer (P0WT5) was used in all cases. The 3  primers 
were designed to allow the cDNAs to be inserted in frame with the 
flag sequence in the pCMV-Tag4 vector. SP, signal sequence; EC, 
extracellular domain; TM, transmembrane domain; IC, intracellular 
domain. (B) P0 mRNA is expressed in L cells transfected with the P0 
constructs as determined by RT-PCR using the specific primers 
shown in A. Primers specific to the enzyme HPRT were used to 
compare expression levels between cell lines. Numbers to the right 
of the figure represent the migration of molecular markers. (C) Full-
length and mutant P0s are expressed at the cell surface in trans-
fected L cells. Cell membrane proteins were labeled with biotin, 
and P0 was precipitated with an anti-P0 antibody. The immunopre-
cipitates were fractionated by SDS-PAGE, transferred to PVDF mem-
branes, and probed with HRP-streptavidin. WT, full-length P0;  13, 
 28,  43, and  59, P0 constructs lacking the terminal 13, 28, 43, 
or 59 amino acids, respectively; Vect, L cells transfected with empty 
vector. Numbers to the left of the figure represent the migration of 
molecular markers. 
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in the presence of P0 is not universal and may depend on a
basal level of cadherin expression and P0 adhesive function or
signaling mediated by the cytoplasmic domain.
 
A PKC target motif and PKC activity are essential for 
P0-mediated adhesion
 
To investigate the importance of the RSTK motif and the
adjacent serine, we assayed L cells transfected with P0 con-
taining mutations in the RSTK motif (S199A and T200A)
 
and in serine 204 (S204A) for their ability to form ho-
mophilic P0 adhesions. In addition, we assayed cells bearing
a mutation at serine 197 (S197A), a site of low level in vivo
phosphorylation (Hilmi et al., 1995), aspartic acid 195
(D195A), and tyrosine 191 (Y191A) as controls. Stable cell
lines were created and tested for P0 expression by RT-PCR
and immunoprecipitation of cell surface labeled P0 as above.
All constructs were expressed at the cell surface (unpublished
data). Cells expressing P0 mutated at serine sites 199 or 204
or threonine 200 failed to form P0-mediated adhesions (Fig.
3 A), indicating that both the PKC motif and serine residue
204 are functionally important. In contrast to these muta-
tions, substitution of serine 197 or aspartic acid 195 have lit-
tle or no effect (Fig. 3 A). Furthermore, replacement of tyro-
sine 191, a site shown recently to be phosphorylated in vivo
(Xu et al., 2000a) with alanine, also has little or no effect on
P0-mediated adhesion (Fig. 3 A).
To further examine the importance of the PKC function
in P0-mediated adhesion, we tested the effect of the PKC in-
hibitor, calphostin C (Tamaoki and Nakano, 1990; Svetlov
and Nigam, 1993). Calphostin C inhibits P0-mediated ad-
hesion in a dose-dependent manner with maximum inhibi-
tion at 60 nM (Fig. 3 B). At this concentration (60 nM),
calphostin has no detectable effect on cell viability as mea-
sured by Sytox green (Molecular Probes).
 
Mutation within the RSTK domain (R198S) causes the 
demyelinating peripheral neuropathy CMT1B and loss 
of P0 homophilic adhesion
 
We have identified an individual with CMT1B who is het-
erozygous for a P0 mutation producing a substitution of argi-
nine for serine at amino acid 198 (R198S) within the PKC
binding motif. The patient had normal growth, development,
and motor function until 5 yr ago, in his late 30s, when he
noted the onset of lower extremity clumsiness; however, these
symptoms have not progressed notably since that time. On
neurological examination, he had minimal symmetrical foot
dorsiflexor weakness, a mild decrease in both large and small fi-
ber sensory modalities (vibration and pin prick) in his feet, and
diminished Achilles and patellar deep tendon reflexes. His gait
appeared normal, but he was unable to walk on his heels, con-
firming the mild weakness of the foot dorsiflexors. In addition,
he had bilateral pes cavus, a common finding in patients with
inherited neuropathy, probably caused by weakness of the in-
trinsic muscles of the feet. On electrophysiological testing, the
nerve conduction velocities of peroneal and tibial motor nerves
were slowed bilaterally to 
 
 
 
25 m/s, whereas his right sural sen-
sory NCV was slowed to 28 m/s. The left sural potential was
unobtainable. These neurological signs and symptoms and elec-
trophysiological findings are consistent with the presence of a
mild demyelinating sensory and motor peripheral neuropathy.
To determine if this mutation affected P0 homophilic ad-
hesion, we transfected L cells with P0 bearing this mutation.
Expression was assayed as above and was found approxi-
mately equivalent to other P0 constructs in L cells (unpub-
lished data). These cells showed a much reduced ability to
form P0 homophilic adhesions (Fig. 3 C). Thus, elimination
of PKC target residues or alteration of the PKC target motif
not only abolishes P0 adhesive function in vitro but also
causes demyelinating disease in humans.
Figure 2. Identification of a region in the cytoplasmic domain of 
P0 that is essential for P0-mediated adhesion. (A) L cells stably 
expressing full-length or truncated P0 were labeled with a vital 
fluorescent dye and assayed for adhesion to monolayers of L cells 
expressing full-length P0. Adherent cells were determined by mea-
suring the amount of fluorescence associated with the cell layers. 
Adhesion of L cells bearing full-length P0 was considered 100% and 
used to calculate adhesion of the other lines. Each cell type was 
assayed in triplicate. (B) HeLa cells stably expressing full-length or 
truncated P0 were assayed for adhesion as described in A. WT, full-
length P0;  13,  28,  43,  59, P0 bearing deletions of the terminal 
13, 28, 43, and 59 amino acids, respectively; Vect, L cells trans-
fected with empty vector. Bars represent the standard deviation 
from the mean (p   0.0001). 
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PKC
 
 
 
 and the PKC binding protein RACK1 are 
associated with P0 in situ
 
The functional requirement for the PKC target motif in P0
and its importance to human disease led us to determine
which of the many isoforms of PKC is present in sciatic
nerve. We find that two conventional PKCs, 
 
 
 
 and 
 
 
 
, are
detected, as well as the novel isoforms 
 
 
 
, 
 
 
 
, and 
 
 
 
 (Table I).
All of these isoforms are also detected in P0-transfected L
cells (Fig. 4, none). However, P0 immunoprecipitates from L
cells lysed in neutral detergent reveal that only PKC
 
 
 
 is present
in association with P0 (Fig. 4). Furthermore, PKC
 
 
 
 is present
and associated with P0 in cultured Schwann cells (Fig. 4, SC).
We further probed P0 immunoprecipitates derived from
each of our deletion mutants for the association of PKC
and the PKC binding protein RACK1. RACKs bind acti-
vated PKC at a site distinct from the substrate-binding site
(Mochly-Rosen et al., 1991) and are thought to target the
enzyme to specific cellular sites independent of PKC sub-
strate recognition (Sim and Scott, 1999; for reviewed see
Jaken and Parker, 2000). As can be seen in Fig. 5, deletion
of the same 14 amino acid sequence containing the RSTK
motif that is essential for P0-mediated adhesion eliminates
the association of PKC
 
 
 
 and RACK1 with P0 (Fig. 5, com-
pare 
 
 
 
13 with 
 
 
 
28 and 
 
 
 
59). However, point mutations al-
tering the RSTK substrate recognition motif or the adjacent
serine 204, mutations that do eliminate P0-mediated adhe-
sion, do not alter PKC or RACK1 binding. Thus, substrate
recognition by PKC and binding, presumably mediated by
RACK1, are two independent events occurring through dis-
tinct sites within a 14 amino acid domain of P0.
 
Discussion
 
In this study, we present data correlating specific amino acid
residues in the cytoplasmic domain of P0 with adhesion func-
tion and ultimately with human disease. By creating a series of
deletions in the cytoplasmic domain, we find that the region
between amino acids 193 and 206 is essential for P0-mediated
adhesion. This region contains a PKC substrate motif (RSTK)
that is one of two major sites of in situ phosphorylation on
 
Figure 3.
 
A PKC target motif and the adjacent serine 204 is essen-
tial for P0-mediated cell adhesion and myelination.
 
 (A) Full-length 
P0 constructs bearing point mutations at the indicated amino acids 
were prepared by PCR and transfected into L cells. Stable clones of 
cells expressing each P0 mutant were selected and assayed for P0-
mediated adhesion as described in the legend to Fig. 2. Adhesion is 
expressed as percent of control, with the control being adhesion of 
L cells expressing full-length P0. Each cell type was assayed in tripli-
cate. WT, cell expressing full-length P0. Mutant cell lines are 
indicated by the specific point mutation. Vect, cell transfected with 
empty vector. (B) Inhibition of PKC activity prevents P0-mediated 
adhesion. L cells expressing full-length P0 were assayed for adhe-
sion in the presence of increasing concentrations of calphostin. 
Adhesion in the absence of the inhibitor was considered 100%. 
Each cell type was assayed in triplicate. (C) A point mutation in the 
PKC target motif results in human disease and loss of P0-mediated 
adhesion in transfected L cells. Stable clones of L cells expressing 
the R198S P0 mutant were assayed for P0-mediated adhesion as 
above. Adhesion is represented as percent of control. Bars represent 
the standard deviation from the mean (
 
p
 
 
 
  
 
0.0001).
 
Table I. 
 
PKC expression in mouse sciatic nerve
Isoform Expression Isoform Expression
Conventional Novel
 
      
      
      
 
Atypical
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serine residues (serine 199) (Hilmi et al., 1995). Using site-
directed mutagenesis, we demonstrate that this motif is im-
portant for adhesive function. A second serine residue at posi-
tion 204, closely juxtaposed to the RSTK site, is also critical
for adhesion function, and this residue is also phosphorylated
in the sciatic nerve (Hilmi et al., 1995). Another serine (197)
that is phosphorylated in situ (Hilmi et al., 1995) does not ap-
pear to be necessary for adhesion function, nor is a tyrosine
residue in the cytoplasmic domain, Y191, which is also phos-
phorylated in sciatic nerve (Iyer et al., 1996).
Of the PKC isoforms present in sciatic nerve and our L cell
model, PKC
 
 
 
 is specifically immunoprecipitated with P0, in-
dicating an in situ association between the two molecules.
This interaction may be mediated by RACK1, the receptor
for activated C kinase, since we find that under our experi-
mental conditions the association of these two proteins is ab-
 
solutely correlated. Furthermore, the association of both pro-
teins with P0 is dependent on a 14 amino acid sequence in the
cytoplasmic domain, amino acids 193–206. This is the same
region containing the PKC substrate motif; however, the sub-
strate site and the binding site are distinct, since point muta-
tions in the substrate site that eliminate adhesion function do
not eliminate binding of PKC or RACK1. RACK1 is one
member of a group of proteins that bind PKC at a site distinct
from the substrate-binding site (Mochly-Rosen et al., 1991;
Sim and Scott, 1999; for review see Jaken and Parker, 2000).
We suggest that RACK1 binds activated PKC and interacts
with P0 either directly or through an additional adaptor to
bring activated PKC
 
 
 
 into substrate proximity.
PKC has been implicated previously in phosphorylation of
P0 in vitro (Suzuki et al., 1990; Rowe-Rendleman and Eich-
berg, 1994) and tumor promoters that activate PKC accentu-
ate phosphorylation in situ (Agrawal and Agrawal, 1989).
Most pertinent to our identification of PKC
 
 
 
 as the critical
isoform, abolition of phorbol 12,13 dibutyrate–induced up-
regulation of PKC in sciatic nerve is accompanied by a re-
duction in PKC
 
 
 
 (Rowe-Rendleman and Eichberg, 1994).
However, these prior studies were not able to correlate the
PKC-dependent phosphorylation of P0 with a specific func-
tion. Our data indicate for the first time that PKC-mediated
phosphorylation on serine residues is important for P0 adhesion
function: P0-mediated adhesion is abolished by mutations of a
PKC target motif, PKC
 
 
 
 and the adaptor RACK1 are immu-
noprecipitated with wild-type P0, and P0-mediated adhesion is
decreased dramatically by calphostin C, a kinase inhibitor that
preferentially blocks PKC activity (IC
 
50
 
 for PKC 
 
  
 
50 nM).
There are two possible mechanisms by which phosphory-
lation of the cytoplasmic domain of P0 may regulate adhe-
sion and/or myelination. One is a direct mechanism in
which phosphorylation of P0 alters its conformation, allow-
ing the cis or trans interactions required for adhesion (Sha-
piro et al., 1996). The second is an indirect mechanism in
which phosphorylation of P0 allows or facilitates the bind-
ing of effector or adaptor molecules essential for adhesion.
In either case, dynamic changes in the phosphorylation state
Figure 4. PKC  coimmunoprecipitates specifically with P0 from 
Schwann cells and L cells expressing full-length P0. Confluent 
cultures of Schwann cells (SC), L cells expressing full-length P0 
(P0wt), and L cells transfected with empty vector (Vect) were lysed 
in nonionic detergent. 1 ml of each cleared cell lysate was immu-
noprecipitated with anti-P0 antibody (P0), and equal aliquots of 
resuspended precipitates were fractionated by SDS-PAGE, trans-
ferred to PVDF, and probed with antibody to the PKC isoform 
indicated. 20  l of each cell lysate, before immunoprecipitation, 
was also fractionated by SDS-PAGE, transferred to PVDF, and blot-
ted with the indicated antibody (lanes labeled none). Numbers to 
the left indicate the migration of prestained standards. Bands due to 
PKC and Ig heavy chain are indicated at the right.
Figure 5. A 14 amino acid sequence in the cytoplasmic domain of 
P0 is essential for its association with PKC  and the PKC binding 
protein RACK1. L cells expressing wild-type P0 (WT) or P0 with 
point mutations or progressive truncations of its cytoplasmic 
domain were lysed in neutral detergent and immunoprecipitated 
with anti-P0 antibody (P0) or preimmune serum (Co). The precipi-
tates were fractionated by SDS-PAGE and transferred to PVDF. The 
membranes were cut at the 55 kD marker and the top half probed 
with anti-PKC  antibody, whereas the bottom half was probed with 
anti-RACK1 monoclonal antibody. Cell line indicates L cells trans-
fected with empty vector (Vec), wild-type P0 (WT), P0 lacking the 
13 COOH-terminal amino acids ( 13), P0 lacking the 28 COOH-
terminal amino acids ( 28), P0 lacking the 59 COOH-terminal 
amino acids ( 59), P0 bearing a S197A mutation (S197), P0 bearing 
a S199A mutation (S199), or P0 bearing a S204A mutation (S204).
Figure 6. Diagram showing human mutations found in the 
cytoplasmic domain of P0 and the corresponding syndrome. The 
site and type of mutation are indicated. (1) Y152 to Stop; (2) 
nucleotide deletion; (3) 17 nucleotide insertion; (4) Q186 to Stop; 
(5) nucleotide insertion; (6) nucleotide insertion; (7) R198 to S; 
(8) four nucleotide deletions including S204. The amino acid 
sequences deleted to create the several P0 truncated mutants used 
in Fig. 1 are represented as alternating blocks of red and blue. The 
amino acids that prove to be essential for P0-mediated adhesion are 
shown in black, and the point mutations that have no effect are 
shown in green. 
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of P0 would have significant effects on P0-mediated adhe-
sion and/or myelination. Further experiments will clearly be
required to distinguish between these two possibilities.
Our deletion and mutational analysis are consistent with
some of the mutations known to give rise to human neuropa-
thies. There are no known human mutations in the COOH-
terminal 13 amino acids that give rise to pathology (Fig. 6);
the single amino acid change identified in this region
(R215L) appears to have no physiological ramifications (Ne-
lis et al., 1999). Accordingly, we find that deletion of this en-
tire region has no effect on adhesion. Five human mutations
causing neuropathy produce a shift in the reading frame, and
two result in introduction of a stop codon, all altering or de-
leting the PKC target site and/or serine 204. One of the
frame shifts leaves the RSTK motif intact but deletes serine
204. This mutation gives rise to a severe form of CMT1, em-
phasizing the importance of this residue. In addition, we have
identified a patient with CMT1B in which an arginine resi-
due has been changed to a serine within this PKC target mo-
tif (RSTK
 
→
 
SSTK), potentially eliminating the ability of
PKC to phosphorylate residues critical to adhesive function
(Fig. 6). Indeed, mimicking this mutation in our in vitro as-
say abolishes P0 homophilic adhesion. Thus, these data im-
plicate PKC-mediated phosphorylation of the cytoplasmic
domain of P0 in both the regulation of homophilic adhesion
and myelination. Consistent with this possibility, mutations
in a dual specificity phosphatase, myotubularin-related pro-
tein-2, cause an autosomal recessive form of demyelinating
CMT, called CMT4B (Bolino et al., 2000). Although it is
not yet known whether myotubularin-related protein-2
cleaves phosphate groups on P0, these results clearly demon-
strate that a phosphorylation/dephosphorylation cascade
plays a role in the regulation of normal PNS myelination.
Given the central role that P0 plays in myelination, it is
likely that other components interact with the cytoplasmic
domain to further regulate the process of myelination. Thus,
P0 mutations that may have profound effects on the process
of myelination independent of its adhesive function will ren-
der incomplete any correlation between adhesion itself and
severity of disease. Recent work from our group emphasizes
this point, since the expression of P0 has dramatic effects on
the levels of expression of other myelin proteins important
for myelination (Xu et al., 2000b). Additionally, the possi-
bility that tyrosine 191 plays a role independent of adhesive
function is suggested by the fact that mutation has no effect
on adhesion, yet the array of polypeptides precipitated with
anti-P0 antibody is altered by its phosphorylation (Xu et al.,
2000a). We expect that a full accounting of the molecular
machinery associated with the cytoplasmic domain of P0
will reveal many more effectors and adaptors as is the case
for the cytoplasmic domains of other Ig superfamily adhe-
sion molecules (for review see Crossin and Krushel, 2000)
and for cadherin (Vleminckx and Kemler, 1999) and inte-
grin (Aplin et al., 1998) adhesion molecules.
 
Materials and methods
 
Antibodies
 
Polyclonal anti-P0 was prepared using a synthetic peptide specific to a 12
amino acid fragment (TWRYQPEGGRDA) from the extracellular domain of
rat P0 as immunogen (Bio-Synthesis Inc.). The antiserum was affinity puri-
 
fied on immobilized peptide and recognizes an 
 
 
 
27 KD P0 molecule in
the rat sciatic nerve (unpublished data). Antipan cadherin antibody is from
Sigma-Aldrich. Antibodies to PKC isoforms and RACK1 were from Trans-
duction Laboratories. HRP-conjugated anti–mouse or –rabbit IgG were
from Cappel Laboratories (ICN Biomedicals). The secondary antibodies
conjugated to magnetic beads used in immunoprecipitations were ob-
tained from PerSeptive Biosystems.
 
Cloning the wild-type P0 and creating a series of mutated
P0 constructs
 
The coding sequences of full-length wild-type P0 (P0WT) and P0 COOH-
terminal deletion mutants were cloned into the pCMV-Tag4 expression
vector (Stratagene) using a PCR-based technique. These various mutants
contain deletions at the COOH terminus of the P0 cytoplasmic domain
lacking the last 13 (
 
 
 
13), 28 (
 
 
 
28), 43 (
 
 
 
43), or 59 (
 
 
 
59) amino acids. All
constructs were created using the same forward primer (P0WT5, ATAG-
GATCCCACCATGGCTCCTGGGGCTC), containing a BamHI restriction
site and a Kozak consensus sequence. The reverse 3
 
 
 
 primers were de-
signed to contain overlapping DNA sequence according to the position of
the deletion followed by a stop codon and a XhoI restriction site (Fig. 1 A):
P0WT3, ATACTCGAGTTTCTTATCCTTGCGAGAC; 
 
 
 
13flag, ATACTC-
GAGGTCGTCCTCGCCAC; 
 
 
 
28flag, ATACTCGAGATACAGCACTGGC-
GTCT; 
 
 
 
43flag, ATACTCGAGAGACTTGTGAAATTTCCCCT; and 
 
 
 
59flag,
ATACTCGAGGGCAGCCTGCCTGCGCAG.
All constructs were cloned into pCMV-Tag4 and tested by restriction
enzyme cleavage and sequenced to ensure that the insertions were in
frame and that no mutations were introduced during PCR.
 
Site-directed mutagenesis
 
Recombinant PCR was used to introduce point mutations in the P0 cyto-
plasmic domain substituting the natural amino acids with alanine residues.
The oligonucleotide primers for point mutations were as follows. The un-
derlined bases indicate the changes from the naturally occurring nucle-
otides: forward Y191A, 5
 
 
 
-AGACCCCAGTGCTGGCTGCCAT-3
 
 
 
; reverse
Y191A, 5
 
 
 
-TGGTCCAGCATGGCAGCCAGCACT-3
 
 
 
; forward D195A, 5
 
 
 
-
TGCTGGCCCACAGCCGAA-3
 
 
 
; reverse D195A, 5
 
 
 
-TGCTTCGGCT-
GTGGGCCAGCA-3
 
 
 
; forward S197A, 5
 
 
 
-CTGGACCACGCTCGAAGCAC-
CAAA-3
 
 
 
; reverse S197A, 5
 
 
 
-AGCTTTGGTGCTTCGAGCGTGGT-3
 
 
 
; for-
ward S199A, 5
 
 
 
-CTGGACCACAGCCGAGCTACCAAA-3
 
 
 
; reverse S199A,
5
 
 
 
-AGCTTTGGTAGCTCGGCTGTGGT-3
 
 
 
; forward T200A, 5
 
 -CACAGC-
CGAAGCGCCAAAGCT-3 ; reverse T200A, 5 -TGGCAGCTTTGGCGCT-
TCGGCT-3 ; forward S204A, 5 -AAGCACCAAAGCTGCCGCTGAGAA-3 ;
and reverse S204A, 5 -ATTTCTTCTCAGCGGCAGCTT-3 .
All mutant constructs were confirmed by sequencing. The constructs
were named Y191A, D195A, S197A, S199A, T200A, S204A, and R198,
respectively.
Transfection of L and HeLa cells
All of the constructs and pCMV-Tag4 without inserts (Vect) were trans-
fected into mouse L cells. WTP0,  13,  28,  43,  59, and Vect were also
transfected into HeLa cells. Stable cell lines were selected for 2 wk in the
presence of 1 mg/ml and maintained in the presence of 200  g/ml of G418
(GIBCO BRL). Single clones were isolated and expanded. Clones of cells
expressing high levels of transfected proteins as determined by immuno-
blotting with anti-P0 serum were chosen for adhesion assays.
RT-PCR
Expression of transfected constructs was assayed by RT-PCR. In brief, total
RNA was isolated from cultured cells using a QIAGEN kit and reverse tran-
scribed with Superscript II and oligo dT primers (GIBCO BRL). The result-
ing cDNA was used to amplify the transfected construct using the same
primers that were used for cloning. For RT-PCR, the hypoxanthine phos-
phoribosyl transferase (HPRT) cDNA was used as an internal control. The
two primers for HPRT amplification were: forward primer, 5 -CACAG-
GACTAGAACACCTGC-3 , and reverse primer, 5 -GCTGGTGAAAAG-
GACCTCT-3 .
Expression of transfected cDNAs
To analyze protein expression of the transfected cDNAs and determine
plasma membrane localization, cell surface molecules were labeled by bio-
tinylation of intact cells followed by immunoprecipitation. Confluent cell lay-
ers in 100-mm dishes were rinsed free of serum and labeled with 0.1 mg/ml
freshly prepared NHS-LC-biotin (Pierce Chemical Co.) in cold PBS for 30
min. After washing and quenching, cell lysates were prepared using 1 ml of
lysis buffer (1.5% NP-40, 0.15 M NaCl, 10 mM Tris, pH 7.2, 5 mM EDTA, 1
mM PMSF, 100  g/ml protease inhibitor cocktail [Sigma-Aldrich], and 100PKC and P0 adhesion | Xu et al. 445
 g/ml DNase) per 100-mm plate, cleared by centrifugation at 14,000 g for 5
min, and the supernatant immunoprecipitated with anti-P0 antibody. The im-
munoprecipitated proteins were separated by SDS-PAGE, transferred to PVDF
membrane, and biotinylated proteins were detected with HRP-streptavidin.
Immunoprecipitation and Western blotting
To analyze the expression of PKC isoforms in sciatic nerve, equal weights
of mouse sciatic nerve were solubilized in 4% SDS, fractionated by SDS-
PAGE, and transferred to PVDF membranes. The membranes were probed
with the indicated anti-PKC isoform antibody followed by HRP-conjugated
anti–mouse IgG and visualized using the extended duration HRP substrate
(Pierce Chemical Co.). For L cells transfected with wild-type P0, cultures
were grown to confluence on 100-mm plates, washed, and incubated free
of serum for 2 h before lysis as indicated above. An aliquot of the lysate
was fractionated by SDS-PAGE and immunoblotted with antibodies to the
PKC isoforms detected in sciatic nerve. The remaining lysate was preincu-
bated with preimmune rabbit serum followed by goat anti–rabbit magnetic
beads. The beads were discarded, and the cleared supernatant was incu-
bated with anti-P0 antibody. The immunoprecipitated P0 and associated
molecules were then fractionated by SDS-PAGE, transferred to PVDF, and
probed with anti-PKC and anti-RACK1 antibodies. The immunoblots were
processed as described above.
Adhesion assays
Cell layers were washed free of serum, harvested using 0.1% trypsin
(GIBCO BRL) in PBS buffer, and resuspended in serum-free medium (DME)
containing 10 mM EDTA at 5   10
6 cells/ml. 2  l/ml of fluorogenic dye
calcein acetoxymethyl ester (calcein AM) (Molecular Probes) were added
to the cell suspensions and incubated at 37 C for 30 min. After two
washes, 5   10
5 single calcein-labeled cells were added to prepared mi-
croplate wells containing confluent monolayers of cells expressing wild-
type P0 or BSA-coated wells as controls. After 1 h incubation at 37 C, the
nonadherent calcein-labeled cells were removed by carefully washing sev-
eral times with DME containing 10 mM EDTA until the BSA-coated wells
had no cells left. The number of cells adhering to the monolayer was mea-
sured with a molecular device microplate reader equipped with a fluores-
cein filter set at 494 nm.
To determine the importance of the PKC motif in the P0 sequence,
calphostin C (Calbiochem) was used to specifically inhibit PKC. Wild-type
P0-transfected cells were preincubated with increasing concentrations of
calphostin C for 1 h and then assayed for adhesion as described above.
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